47th week of 2021 patent applcation highlights part 8 |
Patent application number | Title | Published |
20210361546 | ALKENONE-BASED FORMULATIONS FOR TOPICAL APPLICATIONS - The use of long-chain alkenones to impart desired characteristics in personal care compositions for topical applications is described. The preparation of mixtures long-chain alkenones and synthetic derivatives thereof is presented. Examples of compositions include abrasive soaps, with alkenones serving as natural exfoliating agents. Alkenones and their derivatives can serve as emollients, occlusive agents, encapsulating agents, stabilizing agents, binding agents, thickening agents, surfactants, and antimicrobials. | 2021-11-25 |
20210361547 | FRAGRANCE COMPOSITIONS AND USES THEREOF - According to various embodiments, a composition includes a fragrance component present in an amount of from about 0.04 wt % to about 30 wt %, relative to the total weight of the composition. The fragrance component includes at least one low volatile fragrance material present in an amount greater than 30 wt %, relative to the total weight of the fragrance component. This can be defined as a bottom-heavy fragrance. The fragrance component further includes at least one moderate volatile fragrance material present in an amount of from about 30 wt % to about 70 wt %, relative to the total weight of the fragrance component. The fragrance component further includes at least one high volatile fragrance material present in an amount of from about 0.1 wt % to about 30 wt % relative to the total weight of the fragrance component. | 2021-11-25 |
20210361548 | A SUNSCREEN FORMULATION - The present invention relates to the synthesis of new classes of sunscreen agents, the usage of such sunscreen agents in sunscreen formulations aiming at reduction of sunscreen agents' skin penetration, and a formulation technology using existing sunscreen agents aiming at reduction of sunscreen agents' skin penetration, therefore improving the bio-safety of the sunscreen products. | 2021-11-25 |
20210361549 | ANTIPERSPIRANT - Provided is an antiperspirant which serves to control secretion of sweat secreted from sweat glands and is capable of doing so by acting on sweat glands without closing sweat pores, the antiperspirant containing, as an active ingredient to control secretion of sweat secreted from sweat glands, at least one type of pentacyclic compound selected from the group consisting of compounds represented by formula (I): | 2021-11-25 |
20210361550 | PERSONAL CARE COMPOSITIONS AND METHODS FOR USING SUCH COMPOSITIONS - The present invention relates to sulfate-free aqueous personal care composition comprising a surfactant system comprising at least one methyl oleoyl taurate, one isethionate and one amphoteric or zwitterionic surfactant chosen from (1) amphoacetates and diamphoacetates, (2) sultaines and (3) alkylbetaines, and from about 0.2 pbw to about 15 pbw of a conditioning agent. It is also directed toward the use of such a composition for washing keratin substrates, in particular the hair or the scalp. | 2021-11-25 |
20210361551 | AGENT FOR DYEING HAIR, CONTAINING AT LEAST ONE ORGANIC SILICON COMPOUND, A COLORING COMPOUND AND A FILM-FORMING, HYDROPHILIC POLYMER - The subject of the present disclosure is a composition for coloring keratinous material, in particular human hair, containing in a cosmetic carrier
| 2021-11-25 |
20210361552 | 24-karat Edible Gold Glitter Lipscrub - The present invention is the combined fusion of the sugar and oils based lip scrub with the 24-karat edible Gold dust addictive to enhance the visual purpose of the scrub and provide a hint of sparkle to the lips. The focus of the invention is on the joining of the lip scrub with the 24-karat edible Gold dust addictive. | 2021-11-25 |
20210361553 | SKIN CARE PRODUCT WITH PROTEIN MATRIX - One or more techniques and/or systems are disclosed for formulating a skin care product to mitigate aging or to restore damaged skin. One skin care product includes a blend of growth factors, peptides, and amino acids. Also disclosed is a skin care product formed from a synthesized protein matrix. The synthesized protein matrix can mimic the regenerative effects of human placental proteins, which are desirable when applied to skin because, as skin loses its regenerative properties, humans shows signs of aging, and a decrease in healing capabilities. The exemplary skin-care products disclosed herein can be applied to skin to help mitigate this skin aging process or to restore damaged skin. | 2021-11-25 |
20210361554 | COSMETIC POWDER COMPOSITE AND COSMETIC COMPOSITION CONTAINING SAME - The present invention relates to a powder complex for cosmetics and a cosmetic composition comprising thereof. More specifically, the present invention relates to a powder complex for cosmetics for improving easy-to-clean of the cosmetic powder with water repellency and a cosmetic composition comprising thereof. The powder complex for cosmetic of the present invention has a technical feature that the amphipathic copolymer having a specific structure is adsorbed on the surface of the hydrophobized powder. The cosmetic composition according to the present invention can exhibit an excellent effect of cleaning, with excellent makeup durability. | 2021-11-25 |
20210361555 | FLUID COMPOSITION COMPRISING AN ESTER-TERMINATED POLY(ESTER-AMIDE) POLYMER, A VOLATILE ALKANE, A MONOALCOHOL AND AT LEAST ONE PIGMENT - The present invention relates to a fluid composition, especially comprising a physiologically acceptable medium, especially for coating keratin materials, more particularly for making up and/or caring for keratin materials such as the skin, and containing: a) at least one ester-terminated poly(ester-amide) polymer; and b) at least one volatile alkane; and c) at least one monoalcohol comprising from 2 to 8 carbon atoms; and d) a particulate phase comprising at least one pigment. The invention also relates to a process for coating keratin materials, more particularly for making up and/or caring for keratin materials, such as the skin, characterized in that it comprises the application to the keratin materials of a composition as defined previously. The present invention also relates to a cosmetic assembly comprising—a composition as defined previously—a device for applying said composition to the keratin materials. | 2021-11-25 |
20210361556 | AGENT FOR FORMING FILM ON SKIN - The present disclosure relates to a skin film forming agent, and provides a skin film forming agent which comprises dimethiconol, hydride dimethicone and a cross-linking component, and thereby provides a skin film forming agent which has no problem of safety, and forms a film with high intensity, and thereby can solve peeling and slipping of the film and effectively improve skin disadvantages, particularly, wrinkles and elasticity. | 2021-11-25 |
20210361557 | COMPOSITIONS AND METHODS FOR IMPROVING THE APPEARANCE OF THE SKIN - The disclosure relates to compositions and methods for improving the appearance of the skin. Compositions comprise at least one thermoplastic elastomer, at least one adhesive polymer, and at least one filler. Methods comprise applying the compositions to the skin to tighten the skin or hide skin imperfections by forming a film on the skin. | 2021-11-25 |
20210361558 | HAIR-TREATMENT COMPOSITION AND METHODS OF USE - The present disclosure relates to hair-treatment compositions, which are particularly useful for providing styling, hair manageability, hair care, and conditioning properties to hair. The hair-treatment compositions typically include: (a) about 1 to about 3 wt. % of one or more vegetable oils; (b) about 2 to about 4 wt. % of one or more solid fatty alcohols; (c) 1 wt. % or less of one or more nonionic surfactants; (d) one or more non-silicone shine enhancers; (e) one or more amidoamines: (f) one or more acids; and (g) water. The unique combination of ingredients results in a product having a milky appearance and a fluid viscosity. Kits comprising the hair-treatment compositions and methods of treating hair using the hair-treatment compositions are also disclosed. | 2021-11-25 |
20210361559 | COMPOSITION CONTAINING CIRSIUM JAPONICUM EXTRACT AS ACTIVE INGREDIENT FOR STIMULATING MELANOGENESIS - The present invention relates to a composition for stimulating melanogenesis, comprising | 2021-11-25 |
20210361560 | TOPICAL USE AND DELIVERY OF AMMONIA OXIDIZING MICROORGANISMS - A method of preventing progression of an appearance or effect of aging in a subject is provided. A method of preventing, limiting, or inhibiting injury to skin integrity in a subject is also provided. A method of substantially maintaining a state of skin integrity in a subject is further provided. A method of preventing a topographical change of a cutaneous layer of skin in a subject is still further provided. The methods comprise administering an effective amount of a preparation comprising ammonia oxidizing microorganisms to the subject. Related preparations and kits are also provided. | 2021-11-25 |
20210361561 | A pouch product suitable for application in an oral cavity - The present invention relates to a pouch product suitable for application in an oral cavity of a human comprising a sealable pouch material containing a filling material comprising i) 0 to 10 wt % | 2021-11-25 |
20210361562 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES - Compositions comprising electro-activated aqueous solutions and methods for the prevention and treatment of dysfunctional cardiovascular conditions are provided. | 2021-11-25 |
20210361563 | TRANSDERMAL SYSTEM FOR SYNERGISTIC IMMUNE-CHEMOTHERAPY USING MICRONEEDLES AND METHOD OF TREATMENT THEREOF - Provided herein is a transdermal system for direct local co-delivery of immune checkpoint inhibitor and chemotherapeutic agent by microneedles for synergistic immuno-chemotherapy. Provided herein are lipid-coated nanoparticles and their use to facilitate the drug release and tumor-targeting. Also provided herein is a method of treatment of cancer and other disorder using the system. The present treatment method boost immune response in the tumor microenvironment and enhance the inhibition efficiency for tumor cells and decrease systemic toxicity in a subject unresponsive to systemic therapy. | 2021-11-25 |
20210361564 | Method to reduce face mask and respirator discomfort - Wearing a face mask or a filtering facepiece respirator, especially in hot weather for more than one hour, causes discomfort. But, in a viral pandemic, a barrier to filter inhaled and exhaled air is necessary to protect against airborne pathogens. The sensations of heat abstraction, that is, coolness and cold, can be captured by the rational design of optimized molecules called TRPM8 receptor agonists. The topical application of these molecules alleviates the discomfort of wearing a face mask covering. Several entities were identified by synthesis and experiment as having the ideal properties for achieving this purpose. The preferred embodiments are certain 1-diisopropyl-phosphinoyl-alkanes described as DIPA-1-5, DIPA-1-6, DIPA-1-7, DIPA-1-8, and DIPA-1-9, collectively referred to herein as “DIPA compounds.” The applicant found that topical delivery of DIPA compounds to the facial skin, especially to the surface of the nares (nostrils), alleviates face mask discomfort. From these studies, it is hypothesized that it is the absence of cool air dynamics about the nostrils that causes face mask discomfort. The present discovery pertains to pharmaceutical compositions that relieve face mask discomfort. | 2021-11-25 |
20210361565 | Oral Pharmaceutical Composition of an NK-1 Antagonist - An oral pharmaceutical composition comprising telmapitant, a non-aqueous solvent and one or more additional pharmaceutical acceptable excipients wherein the telmapitant is in solution in the composition. A method of treatment or prevention of emesis in animals comprising administering the oral pharmaceutical composition. | 2021-11-25 |
20210361566 | FORMULATIONS OF 5-HYDROXY TRYPTOPHAN (5-HTP) FOR BETTER BIOAVAILABILITY FOR VARIOUS INDICATIONS - Disclosed herein are a range of gastroretentive sustained release dosage forms that may be particularly useful in the delivery of 5-HTP and other agents that would benefit from delivery to the upper gastrointestinal tract. | 2021-11-25 |
20210361567 | NICOTINE PARTICLES AND COMPOSITIONS - The composition is formed of a plurality of particles. These particles include nicotine, a sugar, and an amino acid or short peptide. | 2021-11-25 |
20210361568 | CANNABINOID-CONTAINING PRODUCTS, CONTAINERS, SYSTEMS, AND METHODS - A dosage device that includes a cannabinoid-containing substance enables controlled addition of the cannabinoid-containing substance to a liquid to produce a cannabinoid-containing liquid for ingestion. In an embodiment, such a dosage device is provided with a container that has a container body holding a liquid and a cover to seal the container body. A dosage device may also or instead be provided with a cover that includes a coupling structure to releasably couple the cover to a liquid container and a seal to seal the container. Other embodiments, including methods of use of a container, methods that involve providing a cannabinoid-containing substance and adding the cannabinoid-containing substance to a cover, and product packages that include multiple covers, are also disclosed. | 2021-11-25 |
20210361569 | Nanostructured Lipid Gel, Method for Preparation and Use - The invention relates to a nanostructured lipid gel formed by alternating layers and vesicles composed of phospholipids, fatty acids and a high water content. The structure and fluidity respond reversibly to temperature and pH, and they are capable of transporting at least one active ingredient within the skin and also to the follicles. The exclusively lipid composition ensures high biocompatibility, and the rheological behaviour facilitates topical and ocular application. | 2021-11-25 |
20210361570 | IN SITU GELLING POLYSACCHARIDE-BASED NANOPARTICLE HYDROGEL COMPOSITIONS, AND METHODS OF USE THEREOF - The present application relates to in situ gelling hydrogel structures formed by the crosslinking of polysaccharide-based nanoparticles and functional polymers. Such systems can be designed to release the nanoparticles and/or encapsulated therapeutics either over time or in response to environmental stimuli. | 2021-11-25 |
20210361571 | NANOSUSPENSIONS OF CANNABIDIOL FOR DEVELOPING WATER-DISPERSIBLE FORMULATIONS - Aqueous nanosuspensions of cannabidiol (CBD) having improved stability, shelf life, and/or CBD content are provided, as are methods of making such nanosuspensions. The nanosuspensions include ethyl maltol as an emulsifying agent and may be manufactured by either a melt emulsification process or a solvent evaporation process. The nanosuspensions may also have an improved taste and are thus suitable for use as, e.g., beverage additives. | 2021-11-25 |
20210361572 | MICELLES AND VESICLES FOR THE DELIVERY OF GLYCOPEPTIDES - Methods for quality control and optimizing the formation and characterization of micelles, vesicles or other aggregates are described herein. Pharmaceutically relevant peptides may be modified to form glycopeptide surfactants which form micelles or other aggregates with another surfactant. Glycopeptide and glycolipid surfactants can aggregate to form particles that enhance drug delivery. The glycopeptide surfactants may be drugs or pro-drugs which are delivered via the micelles or other aggregated structures. | 2021-11-25 |
20210361573 | An Ionic Liquid-Based Nanoemulsion Formulation for the Efficient Delivery of Hydrophilic and Hydrophobic Therapeutic Agents - The present invention discloses an ionic liquid composition comprising an at least partially hydrophobic ionic liquid, wherein the at least partially hydrophobic ionic liquid comprises a di cation comprising two monocationic groups linked by a bridging group wherein the bridging group provides an at least partially hydrophobic character. The composition may also include a hydrophilic ionic liquid. The hydrophobic ionic liquid may include a quaternary ammonium group which may be substituted or unsubstituted, saturated or unsaturated, linear, branched, cyclic or aromatic and the bridging group is a unsubstituted or substituted C | 2021-11-25 |
20210361574 | NANOEMULSION CANNABIS FORMULATIONS AND METHODS OF MAKING SAME - The invention provides a nanoemulsion formulation comprising an aqueous phase, an oil phase dispersed in the aqueous phase, and at least one surfactant. The oil phase includes a cannabis oil. The present invention also provides a preparation that comprises the nanoemulsion formulation. The preparation can be an edible, a beverage, or a pharmaceutical preparation. The present invention still further provides a method of preparing such formulations. | 2021-11-25 |
20210361575 | LIPID PRODRUGS FOR USE IN DRUG DELIVERY - The present disclosure describes the synthesis and use of lipid prodrugs that self-assemble into lipid microbubbles or liposomes. The prodrug-loaded microbubbles or liposomes can be activated intracellularly using an external stimulus, for example, using ultrasound waves. | 2021-11-25 |
20210361576 | LIPOSOME LOADING - Provided herein is technology relating to incorporation of drugs into liposomes and particularly, but not exclusively, to methods for incorporating drugs into liposomes using a weak base and related compositions. | 2021-11-25 |
20210361577 | LIPOPHILIC TRANSPORT PARTICLES FOR COSMETIC OR PHARMACEUTICAL ACTIVE INGREDIENTS - The invention relates to lipophilic transport particles for cosmetic or pharmaceutical active ingredients. The lipophilic transport particles comprise polyglycerol fatty acid ester as a main constituent and, because of the absence of polymorphic transformations, even during long storage, neither have volume changes nor allow the problem of expulsion of the adhering or enclosed active ingredient, due to intense structuring of the crystal lattice and associated compaction, to arise, and therefore the degree of loading with active ingredient and the release profile are stable. | 2021-11-25 |
20210361578 | MEK1/2 INHIBITOR-LOADED MICROPARTICLE FORMULATION - A composition comprising microparticles or liposomes comprising one or more MEK1/2 inhibitors, and methods of using the composition, are provided. | 2021-11-25 |
20210361579 | Thermostable Vaccine Compositions and Methods of Preparing same - Compositions relating to thermostable vaccines and methods of preparing the same. Specifically, methods of preparing thermostable vaccines based on a recombinant ricin neurotoxin protein and uses of co-adjuvants to develop a composition capable of eliciting an immune response in a subject. | 2021-11-25 |
20210361580 | STORAGE STABLE SINCALIDE FORMULATIONS - Disclosed herein are solid compositions that comprise sincalide and are storage stable and which lack a buffer, and optionally, also lack a surfactant/solubilizer, wherein such compositions are storage stable. Also disclosed herein are liquid compositions that comprise sincalide, wherein such compositions are storage stable, and may lack buffer and/or surfactant/solubilizer. Also provided are methods of making and administering the solid or liquid storage stable compositions to a patient in need of, e.g., for the treatment, prevention, and/or diagnosis of gall bladder- and/or pancreatic disorders; or other diagnostic imaging. | 2021-11-25 |
20210361581 | ADDITIVE FOR A POWDER MATERIAL INTENDED FOR COMPACTION INTO SHAPED BODIES - The invention relates to an additive for a powder material intended for compaction into shaped bodies. The additive is used to influence the powder material with regard to its cohesion and slidability on foreign surfaces and comprises as the main constituent one or more polyglycerol fatty acids, each obtained by way of a complete or partial esterification of a linear or branched polyglycerol containing two to eight glyceryl units with one or more fatty acids, each containing 6 to 22 carbon atoms. | 2021-11-25 |
20210361582 | COLCHICINE SALICYLATE DERIVATIVES AND METHODS OF TREATMENT - Pharmaceutical compositions of colchicine salicylate, including once-a-day orally administered formulations are provided. Method of treating and/or preventing cardiovascular disease and/or inflammatory disease in mammalian subjects comprising the administration of the novel formulations disclosed herein is also provided. | 2021-11-25 |
20210361583 | STABILIZED MICROCAPSULES, METHOD OF THEIR PREPARATION AND USES THEREOF - The present application is directed to stabilized core-shell microcapsules comprising a core of benzoyl peroxide (BPO) or all trans retinoic acid (ATRA) and a metal-oxide shell; and to pharmaceutical compositions and methods of use thereof. | 2021-11-25 |
20210361584 | OPTICALLY-INDUCED AUTO-ENCAPSULATION - The present disclosure provides methods and systems for optically-induced auto-encapsulation. A method of the present disclosure comprises providing a media chamber comprising a medium comprising (i) a three-dimensional (3D) object comprising a photo-emitter, (ii) at least one polymeric precursor, and (iii) a photoinitiator, and subjecting the medium in the media chamber to a stimulus (e.g., an energy beam or a chemical stimulus) to induce photo-emission from the photo-emitter to trigger the formation of a polymer matrix from the at least one polymeric precursor, which polymer matrix at least partially encapsulates the 3D object. | 2021-11-25 |
20210361585 | Process for preparing a coated hard shell capsule - A process prepares a polymer-coated hard shell capsule, suitable as container for pharmaceutical or nutraceutical biologically active ingredients. The hard shell capsule can include a body and a cap. In the closed state, the cap overlaps the body either in a pre-locked state or in a final-locked state. The hard shell capsule can be provided in the pre-locked state and spray-coated with a coating solution, suspension, or dispersion that includes a polymer or a mixture of polymers to create a coating layer which covers the outer surface of the hard shell capsule in the pre-locked state. | 2021-11-25 |
20210361586 | STABILIZED MICROCAPSULES, METHOD OF THEIR PREPARATION AND USES THEREOF - The present application is directed to stabilized core-shell microcapsules comprising a core of benzoyl peroxide (BPO) or all trans retinoic acid (ATRA) and a metal-oxide shell; and to pharmaceutical compositions and methods of use thereof. | 2021-11-25 |
20210361587 | COATING MATERIAL FOR USE IN AN HMC METHOD - The invention relates to a coating material for use in a hot-melt coating method, said material containing as the main constituent one or more polyglycerol fatty acid, each obtained by way of a complete or partial esterification of a linear or branched polyglycerol containing two to eight glyceryl units with one or more fatty acids, each containing 6 to 22 carbon atoms. | 2021-11-25 |
20210361589 | ATHLETIC PERFORMANCE ENHANCEMENT COMPOSITION USING MENTHOL - The present invention is directed to an ingestible athletic performance enhancement composition comprising l-menthol wherein the composition does not contain alcohol. The present invention further includes athletic performance enhancement compositions wherein the amount of l-menthol is between 0.01 to 0.5 weight percent of the composition. The invention also includes methods of improving athletic performance comprising the ingestion of a composition comprising l-menthol, wherein the amount of l-menthol is sufficient to induce a cooling sensation while maintaining palatability and minimizing side effects. | 2021-11-25 |
20210361590 | CANNABIDIOL AND ACTIVE DELIVERY SYSTEMS - A cannabidiol (CBD) gelled delivery system comprising: a rheology modifier; an emollient; and one or more cannabidiols selected from the group consisting of a cannabidiol broad spectrum oil, a cannabidiol full spectrum oil, or a cannabidiol isolate. A CBD emulsified delivery system comprising: a rheology modifier; an emollient; a polyglyceryl ester surfactant; and one or more cannabidiols selected from the group consisting of a cannabidiol broad spectrum oil, a cannabidiol full spectrum oil, or a cannabidiol isolate. For such delivery systems, the cannabidiols contain less than 0.3 wt. % of tetrahydrocannabinol (THC) or the cannabidiols are substantially free of THC. An active gelled delivery system a rheology modifier; an emollient; and one or more actives. An active emulsified delivery system comprising: a rheology modifier; an emollient; a polyglyceryl ester surfactant; and one or more actives. | 2021-11-25 |
20210361591 | COMPOSITIONS FOR TREATING ACNE AND DERMATOLOGICAL CONDITIONS - The present disclosure generally relates to compositions comprising unique combinations of cannabinoids, antioxidants, and cofactors. The present disclosure also provides methods of making the compositions and methods for using the compositions for the treatment of mitochondrial ATP deficit disorders. | 2021-11-25 |
20210361592 | COMPOSITION COMPRISING CANNABINOIDS FOR RELIEF OF PAIN - The present technology generally relates to compositions comprising cannabinoids for relieving pain in a subject and to methods of using such compositions for relieving pain in a subject. | 2021-11-25 |
20210361593 | PHYTONADIONE COMPOSITIONS AND RELATED METHODS - Stable Phytonadione compositions for parenteral administration are provided which comprise (E) isomer of phytonadione at or greater than 97% w/w as the active ingredient, and is substantially free of (Z) isomer. Said compositions are stable, sterile, and particulate-free. Further, said compositions reduce or avoid allergic reactions to benzyl alcohol and polysorbate. In some aspects, the compositions are free or substantially free of benzyl alcohol and/or reduced amounts of polysorbate. Methods of manufacture and methods of administration also provided. | 2021-11-25 |
20210361594 | EPINEPHRINE SPRAY FORMULATIONS - Provided herein are epinephrine spray formulations. Also provided herein are methods of treating anaphylaxis by administering epinephrine spray formulations to subjects in need of such treatment. | 2021-11-25 |
20210361595 | EPINEPHRINE SPRAY FORMULATIONS - Provided herein are epinephrine spray formulations. Also provided herein are methods of treating anaphylaxis by administering epinephrine spray formulations to subjects in need of such treatment. | 2021-11-25 |
20210361596 | LASOFOXIFENE TREATMENT OF BREAST CANCER - The disclosure provides methods for treating estrogen receptor positive (ER | 2021-11-25 |
20210361597 | Synthesis of Ibuprofen Hybrid Conjugates as Anti-Inflammatory and Analgesic Agents - Disclosed herein as ibuprofen hybrid conjugates and methods of their use to reduce inflammation, pain, and fever. The ibuprofen conjugates have potent anti-inflammatory and analgesic properties with low potential for ulcerogenic activity. An exemplary compound is an ibuprofen-amino acid-4-aminophenol hybrid. Also disclosed are methods of treating or reducing inflammation, pain, and fever in a subject. | 2021-11-25 |
20210361598 | COMPOUNDS FOR PREVENTION AND TREATMENT OF POST-INTENSIVE CARE COGNITIVE DYSFUNCTION AND COGNITIVE DYSFUNCTION RESULTING FROM RESPIRATORY DISTRESS - Presented herein, in certain aspects, are methods of preventing, reducing, delaying and treating Post-Intensive Care Cognitive Dysfunction (PICCD) by administering a compound disclosed herein to a subject prior to, during and/or after a stay in an ICU, intubation or connection to a ventilator. Also presented herein, in certain aspects, are methods of treating, preventing, inhibiting, reducing the severity of, or delaying the onset of a cognitive impairment or a cognitive disorder resulting from, or caused by respiratory distress. | 2021-11-25 |
20210361599 | CARMUSTINE FORMULATION - The present invention relates to a composition comprising nitrosourea and pharmaceutically acceptable excipients. In particular, the present invention relates to novel drug delivery systems of carmustine such as nano-suspension and micro-emulsion and its use for the treatment of cancer by intravenous administration. Also provided are methods for preparation of such novel drug delivery systems. | 2021-11-25 |
20210361600 | METHODS FOR INDUCING CHONDROGENESIS - Described herein are compounds and compositions for the amelioration of arthritis or joint injuries by inducing mesenchymal stem cells into chondrocytes using intra-articular administration. | 2021-11-25 |
20210361601 | GHB DOSING - Provided herein are methods of administering GHB formulations for the treatment of narcolepsy and other conditions. | 2021-11-25 |
20210361602 | DOSING METHODS FOR TREATING INFLAMMATORY BOWEL CONDITIONS - The invention provides methods and compositions for local administration of therapeutic agents to the rectum or colon, such as by enema. The methods and compositions are useful for treatment of inflammatory bowel disease, including Crohn's disease and ulcerative colitis. | 2021-11-25 |
20210361603 | METHODS OF TREATING CANCERS HAVING A DEREGULATED NRF2/KEAP1 PATHWAY - The present disclosure relates to a method of treating a subject having cancer that includes selecting a subject having cancer associated with a deregulated NRF2/KEAP1 pathway and administering to the selected subject one or more inhibitors comprising a glutamine transporter inhibitor; a GPD2 inhibitor; or combination(s) thereof. | 2021-11-25 |
20210361604 | Methods and Compositions For Enhancing Synthesis Secretion and Transport of Collagen to Increase Wound Strength - A method for, and medicinal composition for, treatment of mammalian cells for enhancing synthesis, secretion and transport of collagen to increase wound strength, that includes magnesium pyruvate; calcium pyruvate; L proline; citrulline: and a liquid carrier. | 2021-11-25 |
20210361605 | FIXED DOSE COMBINATIONS AND FORMULATIONS COMPRISING ETC1002 AND EZETIMIBE AND METHODS OF TREATING OR REDUCING THE RISK OF CARDIOVASCULAR DISEASE - Disclosed herein are compositions comprising fixed doses of ETC-1002 and Ezetimibe. Also disclosed herein are methods for using fixed doses of ETC-1002 and Ezetimibe. Uses include methods of treating cardiovascular disease or reducing the risk of cardiovascular disease in a subject. Uses also include methods of treating hypercholesterolemia in a subject. | 2021-11-25 |
20210361606 | COMPOSITION FOR TREATMENT OF DRY EYE DISEASE AND MEIBOMIANITIS - The present application relates to compositions for treatment of eye disorders, particularly for treatment of dry eye disease (DED) and meibomianitis, wherein the composition comprises very long chain polyunsaturated fatty acids. Further, the invention provides a method for treatment of DED and meibomianitis of a subject, comprising administering to the subject a composition comprising very long chain polyunsaturated fatty acids derived from natural oils. The compositions for use are suitable for oral and local applications. | 2021-11-25 |
20210361607 | COMBINATION METHODS AND COMPOSITIONS INCLUDING SLEEP THERAPEUTICS FOR TREATING MOOD - Pharmaceutical combinations and methods for using such combinations to treat depression are disclosed. In various embodiments (he pharmaceutical combinations include combinations of omega-3 fatty acids, pharmacological sleep agents, and non-pharmacological sleep therapies, and may include other ingredients such as antidepressants. The present invention relates pharmaceutical combinations and methods for their use to treat depression. | 2021-11-25 |
20210361608 | STABILIZED MICROCAPSULES, METHOD OF THEIR PREPARATION AND USES THEREOF - The present application is directed to stabilized core-shell microcapsules comprising a core of benzoyl peroxide (BPO) or all trans retinoic acid (ATRA) and a metal-oxide shell; and to pharmaceutical compositions and methods of use thereof. | 2021-11-25 |
20210361609 | METHODS AND COMPOSITIONS FOR REDUCING ADIPOCYTE NUMBERS - A method for reducing a subcutaneous fat deposit or a visceral fat deposit in vivo by contacting the fat deposit with a composition of latanoprost encapsulated in a liposome formed solely of egg phosphatidylcholine (EggPC) or palmitoyloleoyl phosphatidylcholine (POPC). Also disclosed are methods for treating steatoblepharon, proptosis, and obstructive sleep apnea associated with excess upper airway fat by injecting into the eyelid, intraconal space, and upper airway fat deposit, respectively, the composition of latanoprost encapsulated in an EggPC or POPC liposome. | 2021-11-25 |
20210361610 | COMPOUNDS CONTAINING S-N-VALERYL-N-{[2'-(1H-TETRAZOLE-5-YL)-BIPHENYL-4-YL]-METHYL}-VALINE AND (2R,4S)-5-BIPHENYL-4-YL-4-(3-CARBOXY-PROPIONYLAMINO)-2-METHYL-PENTANOIC ACID ETHYL ESTER MOIETIES AND CATIONS - A compound comprising of the angiotensin receptor antagonist (ARB) valsartan, the neutral endopeptidase inhibitor (NEPi) (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methylpentanoic acid ethyl ester and one or more monovalent cations such as Na | 2021-11-25 |
20210361611 | TREATMENT OF DISORDERS WITH TASIMELTEON - Tasimelteon improves sleep in individuals experiencing an advance in established bedtime. | 2021-11-25 |
20210361612 | SLOW RELEASE CANNABINOIDS AND PRODUCTS THEREOF - There is provided a plastic material comprising at least one cannabinoid embedded within a structural polymer, wherein the plastic material is formulated to exude the at least one cannabinoid through an outer surface of the plastic material at a therapeutically effective rate for a period of at least a week or at least a month. The plastic material may comprise a liquid-absorbent material embedded within the structural polymer and a carrier oil absorbed into the liquid-absorbent material, wherein at least one cannabinoid is dissolved in the carrier oil. | 2021-11-25 |
20210361613 | AUTOMATED IOT DEVICE CONFIGURATION USING USER PROFILE - The invention relates to a liquid composition comprising a combination of Δ | 2021-11-25 |
20210361614 | ISOFLAVONOID COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER - Provided herein is a pharmaceutical composition comprising an isoflavonoid derivative and a cyclodextrin. Also provided herein are methods of treating cancer, sensitizing cancer cells, and inducing apoptosis in cancer cells by administering such compositions. In specific instances, provided herein are intravenous compositions and therapies. | 2021-11-25 |
20210361615 | AMELIORATING AGENT FOR FEMALE-SPECIFIC PHYSICAL AND/OR MENTAL UNPLEASANT SYMPTOM - An ameliorating agent for a female-specific physical and/or mental unpleasant symptom, which contains γ-tocopherol and/or equol. A method of ameliorating a female-specific physical and/or mental unpleasant symptom, the method including administering γ-tocopherol and equol, wherein 0.1 to 1000 mg per day of γ-tocopherol and 0.1 to 50 mg per day of equol are administered. | 2021-11-25 |
20210361616 | AMELIORATING AGENT FOR FEMALE-SPECIFIC PHYSICAL AND/OR MENTAL UNPLEASANT SYMPTOM - An ameliorating agent for a female-specific physical and/or mental unpleasant symptom, which contains γ-tocopherol and/or equol. A method of ameliorating a female-specific physical and/or mental unpleasant symptom, the method including administering γ-tocopherol and equol, wherein 0.1 to 1000 mg per day of γ-tocopherol and 0.1 to 50 mg per day of equol are administered. | 2021-11-25 |
20210361617 | ASCORBIC ACID FORMULATION - An object of the present invention is to provide an ascorbic acid formulation that can be prepared by a simple method, and that has a reduced unpleasant taste and coloration. The inventors found that an ascorbic acid formulation that is in the form of a water-in-oil type emulsion, that comprises an aqueous phase with a pH of 4 or more and an average particle size of 300 nm or less, and that has a mass ratio of water/ascorbic acid of 0.05 to 0.40 has a reduced unpleasant taste and coloration; and accomplished the present invention. Additionally, the present invention can be prepared by a simple method. | 2021-11-25 |
20210361618 | TRIPLET COMBINATION FORMULATIONS AND METHODS FOR TREATING OR REDUCING THE RISK OF CARDIOVASCULAR DISEASE - Disclosed herein are compositions comprising ETC-1002; Ezetimibe; a statin; and one or more pharmaceutical excipients or carriers. Also disclosed herein are methods for using said composition. Uses include methods of treating cardiovascular disease or reducing the risk of cardiovascular disease in a subject. Uses also include methods of treating hypercholesterolemia and/or dyslipidemias in a subject. | 2021-11-25 |
20210361619 | COMPOSITION FOR PREVENTING OR TREATING SARS CORONAVIRUS 2 INFECTION DISEASE - Disclosed is a pharmaceutical composition for preventing or treating severe acute respiratory syndrome coronavirus 2 infection disease, the composition comprising a compound represented by a Chemical Formula 1, or a pharmaceutically acceptable salt thereof, as an active ingredient. | 2021-11-25 |
20210361620 | SLEEP ENHANCEMENT WITH A PROTEIN-BOUND TRYPTOPHAN AND MELATONIN MIXTURE - A composition comprising, preferably, at least partially defatted meal from a plant source containing protein-bound tryptophan that, preferably, has a higher tryptophan source than said plant source, a melatonin component, and a pharmaceutically-acceptable diluent or carrier therefor for enhancing sleep quality and duration in a mammal. In some embodiments, the composition includes a carbohydrate. The invention provides a method of enhancing sleep quality in a mammal having a composition described above. | 2021-11-25 |
20210361621 | Compositions and Methods for Reducing Weight Gain - The present invention provides methods for using reutericyclin or an analog thereof to reduce weight gain or induce weight loss in a mammal. Also provided herein are methods for using reutericyclin-producing | 2021-11-25 |
20210361622 | BLEND CONTAINING CARBAMATE COMPOUND FOR PREVENTION, MITIGATION, OR TREATMENT OF SCHIZOPHRENIA - The present invention relates to a blend for prevention, mitigation, or treatment of schizophrenia, the blend containing a carbamate compound of chemical formula 1, or a pharmaceutically acceptable salt, solvate, or hydrate thereof and, more specifically, to a blend and a pharmaceutical composition each containing a carbamate compound of chemical formula 1 and aripiprazole, and to a use thereof for treating schizophrenia. | 2021-11-25 |
20210361623 | THIOUREYLENE LIQUID COMPOSITIONS - The present invention relates to novel liquid compositions and formulations containing a thioureylene compound, a polysaccharide and a liquid vehicle. The compositions and formulations of the invention are useful for dealing with diseases and conditions associated with abnormally high thyroid hormone levels in mammals, such as humans and cats. | 2021-11-25 |
20210361624 | USE OF A BISAMIDE DERIVATIVE OF MALONIC ACID FOR TREATING ALLERGIC AND OTHER DISEASES IN HUMANS AND ANIMALS - The invention relates to the therapy of diseases associated with the activity of histamine receptors, in particular for the treatment of allergic diseases, preferably the therapy of perennial and persistent allergic rhinitis, itch, as well as a number of other diseases associated with the activity of histamine receptor type 3 and/or 4, using compound N,N′-bis(2-(1H-imidazol-5-yl)ethyl)malonamide. | 2021-11-25 |
20210361625 | COMPOSITIONS AND METHODS FOR TREATING PRESBYOPIA - Compositions for treating presbyopia may include active pharmaceutical ingredients of pilocarpine HCl, phenylephrine HCl, pheniramine maleate, and ketorolac tromethamine. Other ingredients may include boric acid, polyethylene glycol, propylene glycol, and BAK (benzalkonium chloride). The pilocarpine HCl may be in a range of 0.1% to 2%. The phenylephrine HCl may be in a range of 0.1% to 1.5%. The pheniramine maleate may be in a range of 0.07% to 0.35%. The ketorolac tromethamine may be in a range of 0.01% to 0.6%. The boric acid may be in a range of 0.5% to 1.5%. The polyethylene glycol may be in a range of 0.1% to 1%. The propylene glycol may be in a range of 0.1% to 1%. The BAK may be in a range of 0.005% to 0.01%. The solvent may be mostly water. | 2021-11-25 |
20210361626 | CRYSTALLINE PRODUCT - The present invention provides a molecular complex of binimetinib, which is binimetinib dimethylsulfoxide (DMSO) solvate. It is also an object of the present invention to provide a molecular complex of binimetinib which is a crystalline molecular complex of binimetinib and citric acid. The present invention also relates to methods for the preparation of these molecular complexes. | 2021-11-25 |
20210361627 | IL-8 INHIBITORS FOR USE IN THE TREATMENT OF SOME SARCOMAS - The present invention relates to IL-8 inhibitor compounds, preferably dual CXCR1/CXCR2 receptor inhibitors, useful in the treatment and/or prevention of some sarcomas, preferably in the treatment and/or prevention of osteosarcoma, Ewing sarcoma, rhabdomyosarcoma or lung metastasis associated thereof. | 2021-11-25 |
20210361628 | 2-OXOTHIAZOLE COMPOSITIONS FOR TREATMENT OF FIBROTIC DISEASE - A compound of formula (I), (I) wherein R | 2021-11-25 |
20210361629 | THIAZOLIDINEDIONE ANALOGS FOR THE TREATMENT OF NAFLD AND METABOLIC DISEASES - Provided herein are thiazolidinedione analogues that are useful for treating non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), diabetes, and other metabolic inflammation-mediated disease and disorders. | 2021-11-25 |
20210361630 | COMPOSITION COMPRISING COMBINATION OF RAPAMYCIN AND METFORMIN AND USE THEREOF FOR TREATING NEOPLASTIC DISEASES - A formulation for treating neoplastic diseases, including post-transplant malignancies, genetically-driven neoplasia associated with mTORC1 hyperactivation, and a viral associated malignancy comprising a combination of rapamycin and metformin in a molar ratio of about 20:1, 10:1, 5:1, 4:1, 3:1, or 1:1. A method of treating neoplastic diseases comprising administering the formulation comprising a combination of rapamycin and metformin in a molar ratio of about 20:1, 10:1, 5:1, 4:1, 3:1, or 1:1. | 2021-11-25 |
20210361631 | N-methyl-D-aspartic Acid Receptor Modulators - A series of subunit selective allosteric modulators of NMDA receptor function according to Formula (I) is provided herein. Also provided is a method of treating neurological disorders such as Alzheimer's disease Parkinson's disease, schizophrenia, depression, stroke, psychosis and the like using compounds of Formula (I), optionally in combination with one or more further active agent. Pharmaceutical compositions containing a compound of Formula (I) and optionally one or more active agent for treating such disorders may be provided in the form of a tablet, capsule, pill, gel, granules, aerosol, aqueous buffer or a nanoparticle formulation, emulsion, liposome, etc. (I) | 2021-11-25 |
20210361632 | BETAHISTINE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND A MONOAMINE OXIDASE INHIBITOR, FOR USE IN THE TREATMENT OR PREVENTION OF ONE OR MORE SYMPTOMS OF VERTIGO IN A SUBJECT - A first aspect of the invention relates to betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject. | 2021-11-25 |
20210361633 | Methods Of Treating Fabry Patients Having Renal Impairment - Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in α-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day. | 2021-11-25 |
20210361634 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS - Provided herein are pharmaceutical compositions comprising compounds that inhibit Factor XIa or kallikrein and methods of use thereof. | 2021-11-25 |
20210361635 | METHODS FOR TREATING MUSCULAR DYSTROPHIES - Provided herein are methods for treating and preventing a disease related to diminution or dysfunction of a dystrophin-related complex in a subject in need thereof, comprising administering to the subject a compound that increases sarcospan. Also provided herein are pharmaceutical compositions comprising a compound that increases sarcospan, or a pharmaceutically acceptable salt or ester thereof, useful for the treatments described herein. | 2021-11-25 |
20210361636 | FUSED RING COMPOUND HAVING UREA STRUCTURE - The present invention relates to a novel fused ring compound having urea structure that exhibits excellent NAMPT activating effect, and a method using the same for treating/preventing metabolic disorder, cardiovascular and kidney disease, mitochondrial disease, neurodegenerative disease, ocular disease, and muscle wasting disorder. The present invention provides a compound represented by following formula (I) or a pharmacologically acceptable salt: Formula (I) wherein A, B, R, R | 2021-11-25 |
20210361637 | PYRIDINYL SULFONAMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF - The invention relates to new pyridinyl sulfonamide derivatives of the formula | 2021-11-25 |
20210361638 | FXR AGONISTS FOR THE TREATMENT OF LIVER DISEASES - The invention provides methods for treating or preventing a condition mediated by the farnesoid X receptor (FXR), comprising administering tropifexor, a pharmaceutically acceptable salt, an amino acid conjugate or an acyl glucuronide conjugate thereof, at a dose of about 140 μg to about 250 μg, to a subject in need thereof. | 2021-11-25 |
20210361639 | SOLID COMPOSITIONS OF ACTIVES, PROCESSES FOR PREPARING SAME AND USES OF SUCH SOLID COMPOSITIONS - The present invention provides a solid composition comprising nanoparticles comprising at least one water-insoluble active and at least one oil, dispersed within a water-soluble mixture of at least one hydrophilic polymer and at least one surfactant. Process for preparing such solid compositions and aqueous dispersions of such compositions are also provided. | 2021-11-25 |
20210361640 | BETEL QUID CESSATION THERAPY WITH NICOTINE AND PILOCARPINE - Provided herein are compositions comprising nicotine, or a salt thereof, and pilocarpine, or a salt thereof, useful for reducing the use of betel quid and/or achieving betel quid cessation (e.g., replacement therapy). Also provided herein are methods of using the compositions in reducing the risk of developing or reducing the progression of a disease (e.g., cancer, oral disease, neurological disease, or painful condition). Compositions of the present invention may be administered to a subject with an addiction, e.g., a betel quid addiction, areca nut addiction, and/or nicotine addiction. | 2021-11-25 |
20210361641 | Inhibitors of DUX4 Induction for Regulation of Muscle Function - Disclosed are methods and compositions for the treatment of facioscapulohumeral muscular dystrophy. In some cases, the methods and compositions involve the use of kinase inhibitors include Src, Syk, Abl, Tie, Flt, ErbB, Trk, PRKDC, and Yes families to repress DUX | 2021-11-25 |
20210361642 | WASP-PROTECTING SMALL MOLECULES, COMPOSITIONS, METHODS AND USES THEREOF IN THE TREATMENT OF INNATE AND ACQUIRED IMMUNE-RELATED DISORDERS OR CONDITIONS - The present invention provides specific small molecule compounds that modulate degradation and stability of Wiskott-Aldrich Syndrome protein (WASp), methods and uses thereof in innate and acquired immune-related disorders or conditions, specifically, in primary and secondary immune-deficiencies. | 2021-11-25 |
20210361643 | BIFUNCTIONAL COMPOSITIONS FOR THE TREATMENT OF CANCER - The present invention relates to the use of bifunctional compositions in methods of treating or preventing cancer. The compositions comprise a DNA ligand and a protein ligand for the treatment or prevention of cancer, wherein the DNA ligand interferes with DNA metabolism and the protein ligand interferes with signaling pathways. In particular, the present invention relates to the use of pyronaridine in methods of treating of preventing cancer. The invention also relates to compositions, compounds and medicaments comprising a DNA ligand and a protein ligand, for example, compositions, compounds and medicaments comprising pyronaridine. | 2021-11-25 |
20210361644 | STORAGE-STABLE READY-TO-USE INJECTABLE FORMULATIONS OF TRABECTEDIN - Ready-to-use liquid parenteral formulations are provided that include trabectedin, at least one of a pharmaceutically acceptable solvent, and at least one pharmaceutically acceptable excipient or adjuvant. | 2021-11-25 |
20210361645 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY - Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan. | 2021-11-25 |
20210361646 | METHODS FOR PRODUCING ARIPIPRAZOLE SUSPENSION AND FREEZE-DRIED FORMULATION - Disclosed are a method for producing an aripiprazole suspension, wherein the aripiprazole has a mean particle size of 1 to 10?m, the method comprising the steps of: (a) combining bulk aripiprazole and a vehicle to form a primary suspension; (b) subjecting the primary suspension to first pulverization using e.g., a high shear pulverizing machine, a dispersion machine that applies shear force to a material to be processed, a colloid mill, an ultrasonic dispersion machine, or a high-pressure jet type emulsifying dispersion machine to form a secondary suspension; and (c) subjecting the secondary suspension to second pulverization using e.g., a high-pressure jet type emulsifying dispersion machine to form a sterile final suspension; and a method for producing a freeze-dried formulation from the aripiprazole suspension. | 2021-11-25 |